Insider Selling: Illumina, Inc. (NASDAQ:ILMN) Director Sells 3,300 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $376.50, for a total transaction of $1,242,450.00. Following the completion of the transaction, the director now directly owns 272,616 shares of the company’s stock, valued at approximately $102,639,924. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jay T. Flatley also recently made the following trade(s):

  • On Wednesday, April 24th, Jay T. Flatley sold 3,300 shares of Illumina stock. The shares were sold at an average price of $321.96, for a total transaction of $1,062,468.00.

ILMN stock traded down $58.61 on Friday, hitting $305.05. 8,298,145 shares of the company were exchanged, compared to its average volume of 1,006,873. Illumina, Inc. has a twelve month low of $268.62 and a twelve month high of $380.76. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. The company has a fifty day simple moving average of $344.09. The firm has a market cap of $44.84 billion, a PE ratio of 53.33, a price-to-earnings-growth ratio of 2.59 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company had revenue of $846.00 million during the quarter, compared to analyst estimates of $838.70 million. During the same quarter in the prior year, the business earned $1.45 earnings per share. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. Sell-side analysts predict that Illumina, Inc. will post 6.68 earnings per share for the current year.

Several equities analysts recently commented on ILMN shares. Zacks Investment Research lowered shares of GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 2nd. BidaskClub raised shares of Zumiez from a “sell” rating to a “hold” rating in a research report on Saturday, June 22nd. Cowen upped their price target on shares of Solaredge Technologies from $65.00 to $74.00 and gave the stock an “outperform” rating in a research report on Friday. OTR Global lowered shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. Finally, Deutsche Bank upped their price target on shares of Spirit Airlines from $75.00 to $79.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $341.15.

Institutional investors have recently added to or reduced their stakes in the company. Strategy Asset Managers LLC acquired a new stake in shares of Illumina in the first quarter worth $26,000. Massmutual Trust Co. FSB ADV boosted its stake in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the period. C J Advisory Inc purchased a new position in shares of Illumina in the first quarter valued at $29,000. Lake Point Wealth Management purchased a new position in shares of Illumina in the fourth quarter valued at $30,000. Finally, Sontag Advisory LLC purchased a new position in shares of Illumina in the fourth quarter valued at $34,000. 89.69% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: What does a market perform rating mean?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply